{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:57:50Z","timestamp":1788904670872,"version":"build-2803163510"},"reference-count":60,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Psoriasis is a lifelong disease which requires treatment adherence for successful management. Considering the complexity of this pathology, the combination of active pharmaceutical ingredients with a synergistic mechanism of action can improve the safety and efficacy of the treatment with respect to the conventional monotherapy. Moreover, a fixed dose of therapeutic agents in a topical formulation offers the possibility to simplify administration, reduce the doses of each active ingredient, and improve patient\u2019s compliance. Among the first-line treatments in mild to moderate psoriasis, the formulation of calcipotriol (Cal) and betamethasone dipropionate (BD) in a single vehicle is challenging due to their chemical incompatibility in an aqueous environment and the formation of degradation products. Based on these considerations, this review aims to provide an overview on the biopharmaceutical properties of Cal\/BD fixed-dose combination products available on the market (namely ointment, oleogel, foam, and O\/W cream), highlighting also the novel approaches under evaluation. The main differences among topical formulations are discussed considering the different features of the anatomic districts involved in psoriasis and the patient\u2019s adherence. Moreover, since in vitro experiments are fundamental to evaluate the skin permeation profile during the development of an efficacious medicinal product, special emphasis is given to models proposed to mimic psoriatic lesions.<\/jats:p>","DOI":"10.3390\/pharmaceutics14102085","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T23:09:29Z","timestamp":1664492969000},"page":"2085","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Spotlight on Calcipotriol\/Betamethasone Fixed-Dose Combination in Topical Formulations: Is There Still Room for Innovation?"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-6124","authenticated-orcid":false,"given":"Francesca","family":"Selmin","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Franz\u00e8","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Casiraghi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3560-291X","authenticated-orcid":false,"given":"Francesco","family":"Cilurzo","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/10837450.2016.1143003","article-title":"Formulation Factors Affecting the Isomerization Rate of Betamethasone-17-Valerate in a Developmental Hydrophilic Cream\u2014A HPLC and Microscopy Based Stability Study","volume":"22","author":"Byrne","year":"2017","journal-title":"Pharm. Dev. Technol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13555-017-0196-z","article-title":"Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy","volume":"7","author":"Segaert","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11095-004-9008-0","article-title":"Vitamin D3-Based Conjugates for Topical Treatment of Psoriasis: Synthesis, Antiproliferative Activity, and Cutaneous Penetration Studies","volume":"22","author":"Benisty","year":"2005","journal-title":"Pharm. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.2042-7158.1979.tb13532.x","article-title":"The Stability of Betamethasone-17-Valerate in Semi-Solid Bases","volume":"31","author":"Yip","year":"1979","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Middleton, K.R., and Haines-Nutt, R.F. (1983). The Stability of Diluted Betamethasone 17-Valerate Topical Preparations. Hospital Pharmacy and the Patient, Springer.","DOI":"10.1007\/978-94-011-9723-6_12"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0190-9622(98)70171-9","article-title":"Compatibility of Calcipotriene with Other Topical Medications","volume":"38","author":"Patel","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","first-page":"S55","article-title":"Topical Application of Calcipotriene and Corticosteroids: Combination Regimens","volume":"37","author":"Lebwohl","year":"1997","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/jdv.16077","article-title":"Safety and Efficacy of Topical, Fixed-Dose Combination Calcipotriene (0.005%) and Betamethasone (0.064% as Dipropionate) Gel in Adolescent Patients with Scalp and Body Psoriasis: A Phase II Trial","volume":"34","author":"Eichenfield","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2133.2006.07185.x","article-title":"A Comparative Study of Impairment of Quality of Life in Children with Skin Disease and Children with Other Chronic Childhood Diseases","volume":"155","author":"Beattie","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/09546634.2020.1729335","article-title":"Long-Term Topical Management of Psoriasis: The Road Ahead","volume":"33","author":"Segaert","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Orsmond, A., Bereza-Malcolm, L., Lynch, T., March, L., and Xue, M. (2021). Skin Barrier Dysregulation in Psoriasis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910841"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/1346-8138.12393","article-title":"Defective Barrier Function Accompanied by Structural Changes of Psoriatic Stratum Corneum","volume":"41","author":"Takahashi","year":"2014","journal-title":"J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0925-4439(93)90135-N","article-title":"Ceramide Composition of the Psoriatic Scale","volume":"1182","author":"Motta","year":"1993","journal-title":"Biochim. Biophys. Acta-Mol. Basis Dis."},{"key":"ref_14","first-page":"295","article-title":"The Important Role of Stratum Corneum Lipids for the Cutaneous Barrier Function","volume":"1841","author":"Janssens","year":"2014","journal-title":"Biochim. Biophys. Acta-Mol. Cell Biol. Lipids"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1194\/jlr.RA119000420","article-title":"Effects of Omega-O-Acylceramide Structures and Concentrations in Healthy and Diseased Skin Barrier Lipid Membrane Models","volume":"61","author":"Maixner","year":"2020","journal-title":"J. Lipid Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1365-2133.1993.tb15141.x","article-title":"Skin Barrier Function in Healthy Volunteers as Assessed by Transepidermal Water Loss and Vascular Response to Hexyl Nicotinate: Intra- and Inter-Individual Variability","volume":"128","author":"Oestmann","year":"1993","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lin, Y.-K., Yang, S.-H., Chen, C.-C., Kao, H.-C., and Fang, J.-Y. (2015). Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137890"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kocsis, D., Horv\u00e1th, S., Kem\u00e9ny, \u00c1., Varga-Medveczky, Z., Pongor, C., Moln\u00e1r, R., Mih\u00e1ly, A., Farkas, D., Naszlady, B.M., and F\u00fcl\u00f6p, A. (2022). Drug Delivery through the Psoriatic Epidermal Barrier-A \u201cSkin-On-A-Chip\u201d Permeability Study and Ex Vivo Optical Imaging. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084237"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Mok, B.R., Shon, S.-J., Kim, A.R., Simard-Bisson, C., Martel, I., Germain, L., Kim, D.H., and Shin, J.U. (2022). Structural and Functional Validation of a Full-Thickness Self-Assembled Skin Equivalent for Disease Modeling. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061211"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-016-0564-5","article-title":"Nail Psoriasis: A Review of Treatment Options","volume":"76","author":"Pasch","year":"2016","journal-title":"Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rudnicka, L., Olszewska, M., Goldust, M., Wa\u015bkiel-Burnat, A., Warszawik-Hendzel, O., Doro\u017cy\u0144ski, P., Tur\u0142o, J., and Rakowska, A. (2021). Efficacy and Safety of Different Formulations of Calcipotriol\/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment. J. Clin. Med., 10.","DOI":"10.3390\/jcm10235589"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1081\/DDC-200040297","article-title":"Development of a New Formulation Combining Calcipotriol and Betamethasone Dipropionate in an Ointment Vehicle","volume":"30","author":"Simonsen","year":"2004","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2165\/11207300-000000000-00000","article-title":"Calcipotriol\/Betamethasone Dipropionate: A Review of Its Use in the Treatment of Psoriasis Vulgaris of the Trunk, Limbs and Scalp","volume":"71","author":"McCormack","year":"2011","journal-title":"Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2340\/00015555524348","article-title":"The Psoriasis Bio-Assay for Topical Corticosteroid Activity","volume":"52","author":"Dumas","year":"1972","journal-title":"Acta Derm. Venereol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3109\/09546634.2011.641936","article-title":"Use of a Psoriasis Plaque Test in the Development of a Gel Formulation of Calcipotriol and Betamethasone Dipropionate for Scalp Psoriasis","volume":"24","author":"Hoffmann","year":"2013","journal-title":"J. Dermatol. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/1567201816666190118124439","article-title":"Medicated Foams and Film Forming Dosage Forms as Tools to Improve the Thermodynamic Activity of Drugs to Be Administered through the Skin","volume":"16","author":"Gennari","year":"2019","journal-title":"Curr. Drug Deliv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13555-016-0125-6","article-title":"Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients","volume":"6","author":"Lind","year":"2016","journal-title":"Dermatol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/0021-9797(72)90356-6","article-title":"Biliquid Foams\u2014A Preliminary Report","volume":"40","author":"Sebba","year":"1972","journal-title":"J. Colloid Interface Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cis.2014.12.001","article-title":"Aphron Applications\u2014A Review of Recent and Current Research","volume":"216","author":"Molaei","year":"2015","journal-title":"Adv. Colloid Interface Sci."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Moiseev, R.V., Steele, F., and Khutoryanskiy, V.V. (2022). Polyaphron Formulations Stabilised with Different Water-Soluble Polymers for Ocular Drug Delivery. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14050926"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s13555-022-00794-y","article-title":"Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application","volume":"12","author":"Praestegaard","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_32","unstructured":"Praestegaard, N., Crutchley, M., Georgiou, S., and Morten, L. (2019). Topical Composition Comprising Calcipotriol and Betamethasone Dipropionate. (EP3542788A1), Patent."},{"key":"ref_33","unstructured":"Wheeler, D., Steele, D.F., Georgiou, M., and Sindet-Pedersen, S. (2019). Topical Compositio. (US11065195B2), U.S. Patent."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejpb.2017.03.006","article-title":"Cyclosporine A Delivery to the Eye: A Comprehensive Review of Academic and Industrial Efforts","volume":"117","author":"Lallemand","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11095-020-2766-5","article-title":"Sensitivity of Different In Vitro Performance Tests and Their In Vivo Relevance for Calcipotriol\/Betamethasone Ointment","volume":"37","author":"Kristan","year":"2020","journal-title":"Pharm. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.12788\/j.sder.2016.006","article-title":"Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence","volume":"35","author":"Gold","year":"2016","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejpb.2021.04.016","article-title":"Improved Imiquimod-Induced Psoriasis like Dermatitis Using Microneedles in Mice","volume":"164","author":"Liang","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_38","unstructured":"Microneedle Patch for Psoriatic Plaques (2022, August 04). ClinicalTrials.gov Identifier: NCT02955576, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02955576."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjd.15779","article-title":"A Hyaluronic Acid-Based Microneedle Patch to Treat Psoriatic Plaques: A Pilot Open Trial","volume":"178","author":"Lee","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1517\/17425247.2014.938634","article-title":"Solid Lipid Nanoparticles-Loaded Topical Gel Containing Combination Drugs: An Approach to Offset Psoriasis","volume":"11","author":"Sonawane","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"102328","DOI":"10.1016\/j.jddst.2021.102328","article-title":"Nano-Enabled Topical Delivery of Anti-Psoriatic Small Molecules","volume":"62","author":"Bhat","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/17425247.2020.1758665","article-title":"Trends in Nanotechnology-Based Delivery Systems for Dermal Targeting of Drugs: An Enticing Approach to Offset Psoriasis","volume":"17","author":"Saleem","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamadermatol.2016.0859","article-title":"Efficacy of Novel Topical Liposomal Formulation of Cyclosporine in Mild to Moderate Stable Plaque Psoriasis: A Randomized Clinical Trial","volume":"152","author":"Kumar","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ejpb.2012.04.005","article-title":"Calcipotriol Delivery into the Skin with PEGylated Liposomes","volume":"81","author":"Knudsen","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2174\/2211738507666190906123643","article-title":"Development of Topical Gel of Methotrexate Incorporated Ethosomes and Salicylic Acid for the Treatment of Psoriasis","volume":"7","author":"Chandra","year":"2019","journal-title":"Pharm. Nanotechnol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.nano.2017.02.009","article-title":"Nanoemulsion Loaded Gel for Topical Co-Delivery of Clobitasol Propionate and Calcipotriol in Psoriasis","volume":"13","author":"Kaur","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/17425247.2017.1264386","article-title":"Solid Lipid Nanoparticles and Nanostructured Lipid Carrier-Based Nanotherapeutics in Treatment of Psoriasis: A Comparative Study","volume":"14","author":"Arora","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fphar.2013.00091","article-title":"Determinants of Patient Adherence: A Review of Systematic Reviews","volume":"4","author":"Kardas","year":"2013","journal-title":"Front. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/135910539700200409","article-title":"The Physical, Psychological and Social Impact of Psoriasis","volume":"2","author":"Rapp","year":"1997","journal-title":"J. Health Psychol."},{"key":"ref_50","first-page":"581","article-title":"Patients with Psoriasis and Their Compliance with Medication","volume":"41","author":"Richards","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1159\/000446068","article-title":"Topical Corticosteroid Concerns in Dermatological Outpatients: A Cross-Sectional and Interventional Study","volume":"232","author":"Tomaschett","year":"2016","journal-title":"Dermatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jaad.2008.08.028","article-title":"Psoriasis: Improving Adherence to Topical Therapy","volume":"59","author":"Feldman","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Menditto, E., Orlando, V., De Rosa, G., Minghetti, P., Musazzi, U.M., Cahir, C., Kurczewska-Michalak, M., Kardas, P., Costa, E., and Sousa Lobo, J.M. (2020). Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12010044"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/09546634.2019.1675855","article-title":"Psoriasis Patient Preferences for Topical Drugs: A Systematic Review","volume":"32","author":"Svendsen","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2133.2001.04344.x","article-title":"Ointment Is Evenly Spread on the Skin, in Contrast to Creams and Solutions","volume":"145","author":"Ivens","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1208\/s12249-018-1246-2","article-title":"Mechanical Properties of Topical Anti-Psoriatic Medicines: Implications for Patient Satisfaction with Treatment","volume":"20","author":"Teixeira","year":"2019","journal-title":"AAPS PharmSciTech."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/09546634.2018.1473837","article-title":"Patients Preferences for Different Corticosteroid Vehicles Are Highly Variable","volume":"31","author":"Felix","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1080\/03007995.2022.2078099","article-title":"Efficacy, Quality of Life, and Treatment Satisfaction: An Indirect Comparison of Calcipotriol\/Betamethasone Dipropionate Cream versus Foam for Treatment of Psoriasis","volume":"38","author":"Reich","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Papp, K.A., Thoning, H., Gerdes, S., Megna, M., Brandi, H., Bernasconi, M.Y.J., and Y\u00e9lamos, O. (2022). Matching-Adjusted Indirect Comparison of Efficacy Outcomes in Trials of Calcipotriol plus Betamethasone Dipropionate Foam and Cream Formulations for the Treatment of Plaque Psoriasis. J. Dermatol. Treat., 1\u20139.","DOI":"10.1080\/09546634.2022.2095330"},{"key":"ref_60","first-page":"266","article-title":"First-Line Fixed-Combination Psoriasis Treatment Is Associated With Lower Healthcare Costs","volume":"14","author":"Feldman","year":"2016","journal-title":"Skinmed"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/10\/2085\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:42:04Z","timestamp":1760143324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/10\/2085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":60,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["pharmaceutics14102085"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14102085","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]}}}